PUBLICATIONS
"If it were not for the great variability among individuals
medicine might as well be a science and not an art."
Sir William Osler
PEER-REVIEWED ARTICLES
BOUNDED INTEGER MODEL-BASED ANALYSIS OF PSORIASIS AREA AND SEVERITY INDEX IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS RECEIVING BIÂ 730357
Ooi Q, Kristoffersson A, Korell J, Flack M, Plan E, Weber B
Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology | submitted
PARAMETRIC TIME-TO-EVENT MODEL FOR ACUTE EXACERBATIONS IN IDIOPATHIC PULMONARY FIBROSIS
Tang F, Weber B, Stowasser S, Korell J
Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology 2020;9:87-95
DETERMINATION OF PLASMA CONCENTRATION REFERENCE RANGES FOR ORAL ARIPIPRAZOLE, OLANZAPINE AND QUETIAPINE
Korell J, Green B, Rae A, Remmerie B, Vermeulen A
European Journal of Clinical Pharmacology 2018;74(5):593-599
A HUMAN CHALLENGE MODEL FOR RESPIRATORY SYNCYTIAL VIRUS KINETICS, THE PHARMACOLOGICAL EFFECT OF A NOVEL FUSION INHIBITOR, AND THE MODELING OF SYMPTOMS SCORES
Korell J, Green B, DeVincenzo J, Huntjens D
European Journal of Pharmaceutical Sciences 2017;109(Supp):S154-S160
OPTIMIZING ANTIPSYCHOTIC PATIENT MANAGEMENT USING POPULATION PHARMACOKINETIC MODELS AND POINT-OF-CARE TESTING
Green B, Korell J, Remmerie B, Savitz A, Vermeulen A
Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology 2017;6:573–575
A MODEL-BASED LONGITUDINAL META-ANALYSIS OF FEV1 IN RANDOMIZED COPD TRIALS
Korell J, Martin SW, Karlsson MO, Ribbing J
Clinical Pharmacology & Therapeutics 2016;99(3):315-324
SIMPLIFICATION OF A PHARMACOKINETIC MODEL FOR RED BLOOD CELL METHOTREXATE DISPOSITION
Pan S, Korell J, Stamp LK, Duffull SB
Journal of Clinical Pharmacology 2015;71(12):1509-1516
ASSESSMENT OF THE RELATIONSHIP BETWEEN METHOTREXATE POLYGLUTAMATES IN RED BLOOD CELLS AND CLINICAL RESPONSE IN PATIENTS COMMENCING METHOTREXATE FOR RHEUMATOID ARTHRITIS
Pan S, Stamp LK, Duffull SB, Barclay ML, Dalrymple JM, Drake J, Zhang M, Korell J
Clinical Pharmacokinetics 2014;53(12):1161-1170
COMPARISON OF INTRACELLULAR METHOTREXATE KINETICS IN RED BLOOD CELLS WITH THE KINETICS IN OTHER CELL TYPES
Korell J, Duffull SB, Dalrymple JM, Drake J, Zhang M, Barclay ML, Stamp LK
British Journal of Clinical Pharmacology 2014;77(3):493-497
PARAMETERISATION AFFECTS IDENTIFIABILITY OF POPULATION MODELS
Shivva V, Korell J, Tucker IG, Duffull SB.
Journal of Pharmacokinetics and Pharmacodynamics 2014;41(1):81-86
A SEMI-MECHANISTIC RED BLOOD CELL SURVIVAL MODEL PROVIDES SOME INSIGHT INTO RED BLOOD CELL DESTRUCTION MECHANISMS
Korell J, Duffull SB
Journal of Pharmacokinetics and Pharmacodynamics 2013:40(4):469-478
AN APPROACH FOR IDENTIFIABILITY OF POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELS
Shivva V, Korell J, Tucker IG, Duffull SB
Clinical Pharmacology & Therapeutics: Pharmacometrics & Systems Pharmacology 2013;2:e49
A POPULATION PHARMACOKINETIC MODEL FOR METHOTREXATE IN RED BLOOD CELLS
Korell J, Stamp LK, Barclay ML, Dalrymple JM, Drake J, Zhang M, Duffull SB
Clinical Pharmacokinetics 2013;52(6):475-485
A PHARMACOKINETIC MODEL FOR THE GLYCATION OF ALBUMIN
Alskär O, Korell J, Duffull SB
Journal of Pharmacokinetics and Pharmacodynamics 2012;39(3):273-282
MODELLING RED BLOOD CELL SURVIVAL DATA
Korell J, Vos FE, Coulter CV, Schollum JB, Walker RJ, Duffull SB
Journal of Pharmacokinetics and Pharmacodynamics 2011;38(6):787-801
EVALUATION OF RED BLOOD CELL LABELLING METHODS BASED ON A STATISTICAL MODEL FOR RED BLOOD CELL SURVIVAL
Korell J, Coulter CV, Duffull SB
Journal of Theoretical Biology 2011;291(0):88-98
A STATISTICAL MODEL FOR RED BLOOD CELL SURVIVAL TIME
Korell J, Coulter CV, Duffull SB
Journal of Theoretical Biology 2011;268(1):39-49
ORAL PRESENTATIONS
QUANTIFICATION OF DABIGATRAN ANTICOAGULATION REVERSAL:
BAYESIAN ANALYSIS OF THE IDARUCIZUMAB-DABIGATRAN PK BINDING MODEL
Korell J
American Conference on Pharmacometrics (ACoP) 8, 2017, Fort Lauderdale, FL
Invited Speaker
A POPULATION MODEL FOR RESPIRATORY SYNCYTIAL VIRUS KINETICS USING TRANSIT COMPARTMENTS BASED ON HUMAN CHALLENGE DATA
Korell J, Green B, Huntjens D
World Conference on Pharmacometrics (WCoP), 2016, Brisbane, Australia
A POPULATION PKPD MODEL FOR NEUTROPENIA DURING HYPER-CVAD CHEMOTHERAPY IN NON-HODGKIN LYMPHOMA
Sandhu G, Carrington C, Mapp S, Korell J
Population Analysis Group Australia and New Zealand (PAGANZ) 17, 2015, Melbourne, Australia
EXTREMES OF BODY SIZE IN THE DOSING OF HIGH-DOSE METHOTREXATE CHEMOTHERAPY FOR NON-HODGKIN LYMPHOMA
Sandhu G, Carrington C, Mapp S, Hennig S, Korell J
Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists & Toxicologists (ASCEPT), 2014, Melbourne, Australia
ASSESSMENT OF THE RELATIONSHIP BETWEEN METHOTREXATE POLYGLUTAMATES IN RED BLOOD CELLS AND CLINICAL RESPONSE IN RHEUMATOID ARTHRITIS
Pan S, Stamp LK, Duffull SB, Korell J
Annual Scientific Meeting of ASCEPT New Zealand, 2014, Queenstown, New Zealand
APPLICATION OF A MODEL BASED LONGITUDINAL NETWORK META-ANALYSIS OF FEV1 IN COPD TRIALS IN CLINICAL DRUG DEVELOPMENT
Korell J, Martin SW, Karlsson MO, Ribbing J
Population Analysis Group Europe (PAGE) 23, 2014, Alicante, Spain
AÂ LONGITUDINAL MODEL BASED META-ANALYSIS FOR FEV1 IN COPD
Korell J, Martin SW, Karlsson MO, Ribbing J
PAGANZ 16, 2014, Dunedin, New Zealand
SIMPLIFICATION OF A PHARMACOKINETIC MODEL FOR RED BLOOD CELL METHOTREXATE DISPOSITION
Pan S, Korell J, Stamp LK, Duffull SB
PAGANZ 16, 2014, Dunedin, New Zealand
SIMPHARM V2.0: A PATIENT-SIMULATION BASED CLINICAL PHARMACOLOGY TEACHING TOOL FOR PHARMACY STUDENTS
Harper T, Korell J, Duffull SB
Annual Scientific Meeting of ASCEPTÂ New Zealand, 2013, Queenstown, New Zealand
ASSESSMENT OF THE ACTIVITY OF RED BLOOD CELL METHOTREXATE POLYGLUTAMATES
Pan S, Korell J, Stamp LK, Duffull SB
Annual Scientific Meeting of ASCEPT New Zealand, 2013, Queenstown, New Zealand.
IDENTIFIABILITY OF POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELS
Shivva V, Korell J, Tucker IG, Duffull SB
PAGEÂ 22, 2013, Glasgow, UK
DEVELOPMENT OF A SIMPLIFIED MATHEMATICAL MODEL OF THE HUMAN PHYSIOME:Â AN APPLICATION RELATING TO THE CARDIOVASCULAR SYSTEM
Korell J, Duffull SB
PAGANZ 15, 2013, Brisbane, Australia
IDENTIFIABILITY OF POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELS
Shivva V, Korell J, Tucker IG, Duffull SB
PAGANZ 15, 2013, Brisbane, Australia
RED BLOOD CELL SURVIVAL AND ITS INFLUENCE ON CLINICAL BIOMARKERS
Korell J, Duffull SB
WCoP, 2012, Seoul, South Korea
Invited Speaker
PHARMACOKINETICS OF METHOTREXATE IN RED BLOOD CELLS
Korell J, Stamp L, Duffull SB
Annual Scientific Meeting of ASCEPT New Zealand, 2012, Queenstown, New Zealand
ASSESSMENT OF IDENTIFIABILITY OF PHARMACOKINETIC MODELS
Shivva V, Korell J, Tucker IG, Duffull SB
Annual Scientific Meeting of ASCEPT New Zealand, 2012, Queenstown, New Zealand
PHARMACOKINETICS OF METHOTREXATE IN RED BLOOD CELLS
Korell J, Stamp L, Duffull SB
PAGANZ 14, 2013, Melbourne, Australia
DEVELOPMENT AND APPLICATION OF A PHARMACOKINETIC MODEL FOR THE GLYCATION OF ALBUMIN
Alskär O, Korell J, Duffull SB
PAGANZ 14, 2013, Melbourne, Australia
DEVELOPMENT AND APPLICATION OF A PHARMACOKINETIC MODEL FOR THE GLYCATION OF ALBUMIN
Alskär O, Korell J, Duffull SB
Annual Scientific Meeting of ASCEPT New Zealand, 2011, Christchurch, New Zealand
MODELLING RED BLOOD CELL DATA
Korell J, Vos FE, Sanhajariya S, Coulter CV, Schollum JB, Walker RJ, Duffull SB
PAGANZ 13, 2011, Auckland, New Zealand
DESIGN OF SURVIVAL STUDIES FOR RED BLOOD CELLS
Korell J, Coulter CV, Duffull SB
PAGE 19, 2010, Berlin, Germany
DESIGN OF SURVIVAL STUDIES FOR RED BLOOD CELLS
Korell J, Coulter CV, and Duffull SB
PAGANZÂ 12, 2010, Adelaide, Australia
A STATISTICAL MODEL FOR RED BLOOD CELL SURVIVAL TIME
Korell J, Coulter CV, Duffull SB
Annual Scientific Meeting of ASCEPT New Zealand, 2009, Dunedin, New Zealand
POSTER PRESENTATIONS
POPULATION PHARMACOKINETIC MODEL FOR BI 1015550 IN HEALTHY VOLUNTEERS AND PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
Velez de Mendizabal N, Kawakatsu S, Yu Y, Zoz D, Korell J
PAGE 31, 2023, A Coruna, Spain
TIME-TO-EVENT MODEL FOR ACUTE EXACERBATIONS IN IDIOPATHIC PULMONARY FIBROSIS
Tang F, Weber B, Stowasser S, Korell J
Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), 2019, Washington, DC
PREDICTING MORTALITY IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS TREATED WITH NINTEDANIB
Tang W, Menjoge S, Stowasser S, Korell J
American Thoracic Society (ATS) International Conference, 2018, San Diego, CA
A POPULATION MODEL FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) KINETICS USING TRANSIT COMPARTMENTS BASED ON HUMAN CHALLENGE DATA
Huntjens D, Korell J, Green B
ACoP 8, 2017, Fort Lauderdale, FL
DEVELOPMENT OF AN INTERACTIVE TOOL TO EXPLORE PEADIATRIC DOSES AND SAMPLE SIZE FOR PEADIATRIC TRIALS
Cheng M, McDougall D, Korell J, Green B
WCoP, 2016, Brisbane, Australia
PREDICTING REDUCTIONS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
EXACERBATIONS FROM FEV1 – A MODEL-BASED META-ANALYSIS OF LITERATURE
DATA FROM CONTROLLED RANDOMIZED CLINICAL TRIALS
Ribbing J, Korell J, Cerasoli F, Milligan PA, Martin SW, Karlsson MO
PAGEÂ 25, 2016, Lisbon, Portugal
THE DEVELOPMENT AND USE OF POPULATION REFERENCE RANGES AS A TOOL TO INTERPRET ANTIPSYCHOTIC PLASMA CONCENTRATIONS
Vermeulen A, Remmerie B, Korell J, Green B, Savitz A
Annual Scientific Meeting of the Society of Biological Psychiatry (SoBP), 2016, Atlanta, GA
PREDICTING REDUCTIONS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
EXACERBATIONS FROM FEV1 – A MODEL-BASED META-ANALYSIS OF LITERATURE DATA FROM CONTROLLED RANDOMIZED CLINICAL TRIALS
Ribbing J, Korell J, Cerasoli F, Milligan PA, Martin SW, Karlsson MO
ACoP 6, 2015, Washington, DC
A POPULATION PHARMACOKINETIC MODEL FOR ARIPIPRAZOLE + DEHYDRO-ARIPIPRAZOLE
Korell J, Green B, Vermeulen A
PAGEÂ 24, 2015, Hersonissos, Greece
EXTREMES OF BODY SIZE IN THE DOSING OF HIGH-DOSE METHOTREXATE CHEMOTHERAPY FOR NON-HODGKIN LYMPHOMA
Sandhu G, Carrington C, Mapp S, Hennig S, Korell J
ASCEPT, 2014, Melbourne, Australia
PUNCHING ABOVE THE WEIGHT – HIGH-DOSE METHOTREXATE CHEMOTHERAPY IN EXTREMES OF BODY SIZE
Sandhu G, Korell J, Mapp S, Carrington C
Annual Scientific Meeting of the Clinical Oncology Society of Australia (COSA), 2014, Melbourne, Australia
EFFECT OF RANDOM NONCOMPLIANCE ON PLASMA CONCENTRATION TARGETS – A PROOF-OF-CONCEPT ANALYSIS
Korell J, McLeay SC, Green B, Vermeulen A
ACoP 5, 2014, Las Vegas, NV
SIMPLIFICATION OF A PHARMACOKINETIC MODEL FOR RED BLOOD CELL METHOTREXATE DISPOSITION
Pan S, Korell J, Stamp LK, Duffull SB
ACoP 5, 2014, Las Vegas, NV
GAINING INSIGHT INTO RED BLOOD CELL DESTRUCTION MECHANISMS USING A PREVIOUSLY DEVELOPED SEMI-MECHANISTIC MODEL
Korell J, Duffull SB
PAGE 22, 2013, Glasgow, UK
RELATING INTRACELLULAR METHOTREXATE POLYGLUTAMATE CONCENTRATIONS IN RED BLOOD CELLS WITH CLINICAL RESPONSE IN RHEUMATOID ARTHRITIS
Pan S, Korell J, Stamp LK, Duffull SB
PAGANZÂ 15, 2013, Brisbane, Australia
MODELLING RED BLOOD CELL SURVIVAL DATA
Korell J, Vos FE, Coulter CV, Schollum JB, Walker RJ, Duffull SB
PAGEÂ 20, 2011, Athens, Greece
DESIGN OF SURVIVAL STUDIES FOR RED BLOOD CELLS
Korell J, Coulter CV, Duffull SB
Annual Scientific Meeting of ASCEPT New Zealand, 2010, Christchurch, New Zealand